CD274 and neoplasm: A greater response to these treatments has been observed in patients with evidence of an inflamed tumor microenvironment at baseline, as suggested by higher PD-L1 expression, presence of CD8+ lymphocytes, and expression of genes involved in IFNγ signaling.